切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2017, Vol. 06 ›› Issue (02) : 54 -57. doi: 10.3877/cma.j.issn.2095-3216.2017.02.002

所属专题: 文献

专家论坛

蛋白质组学在肾脏疾病研究中的应用
吕杨1, 谢院生1, 陈香美1,()   
  1. 1. 100853 北京,解放军总医院肾脏病科、解放军肾脏病研究所、肾脏疾病国家重点实验室、国家慢性肾病临床医学研究中心
  • 收稿日期:2017-02-13 出版日期:2017-04-28
  • 通信作者: 陈香美

Application of proteomics in kidney disease research

Yang Lv1, Yuansheng Xie1, Xiangmei Chen1,()   

  1. 1. Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing 100853, China
  • Received:2017-02-13 Published:2017-04-28
  • Corresponding author: Xiangmei Chen
  • About author:
    Corresponding author: Chen Xiangmei, Email:
引用本文:

吕杨, 谢院生, 陈香美. 蛋白质组学在肾脏疾病研究中的应用[J/OL]. 中华肾病研究电子杂志, 2017, 06(02): 54-57.

Yang Lv, Yuansheng Xie, Xiangmei Chen. Application of proteomics in kidney disease research[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2017, 06(02): 54-57.

研究肾脏疾病发病机制和生物标志物,有助于临床上提高诊断和治疗水平。蛋白质组学是研究发病机制及生物标志物的重要手段。本文对蛋白质组学的发展历史、主要技术方法以及蛋白质组学在IgA肾病、糖尿病肾病、膜性肾病、急性肾损伤和肾癌研究中的应用做了详尽的阐述,并对日后蛋白质组学在肾脏疾病研究中的应用做了展望。

Study on the pathogenesis and biomarkers of renal diseases can improve the diagnosis and treatment clinically. Proteomics is an important discipline to study the pathogenesis and biomarkers. In this paper, the authors elaborated the context including the development history of proteomics, the main technical methods, and proteomics application in the study of IgA nephropathy, diabetic nephropathy, membranous nephropathy, acute kidney injury, and renal cell carcinoma. A prospect was also made of the application of proteomics in kidney disease research.

[1]
Adachi J, Kumar C, Zhang Y, et al. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins [J]. Genome Biol, 2006,7(9): R80.
[2]
Kentsis A, Monigatti F, Dorff K, et al. Urine proteomics for profiling of human disease using high accuracy mass spectrometry [J]. Proteomics Clin Appl, 2009,3(9): 1052-1061.
[3]
Li QR, Fan KX, Li RX, et al. A comprehensive and non-prefractionation on the protein level approach for the human urinary proteome: touching phosphorylation in urine [J]. Rapid Commun Mass Spectrom, 2010,24(6): 823-832.
[4]
Di Meo A, Batruch I, Yousef AG, et al. An integrated proteomic and peptidomic assessment of the normal human urinome [J]. Clin Chem Lab Med, 2017,55(2): 237-247.
[5]
Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database [J]. Proteomics, 2005, 5(13): 3226-3245.
[6]
Farrah T, Deutsch EW, Omenn GS, et al. A high-confidence human plasma proteome reference set with estimated concentrations in peptideatlas [J]. Mol Cell Proteomics, 2011, 10(9): M110.006353.
[7]
Samavat S, Kalantari S, Nafar M, et al. Diagnostic urinary proteome profile for immunoglobulin a nephropathy [J]. Iran J Kidney Dis, 2015,9(3): 239-248.
[8]
Mucha K, Bakun M, Jazwiec R, et al. Complement components, proteolysisrelated, and cell communication related proteins detected in urine proteomics are associated with IgA nephropathy [J]. Pol Arch Med Wewn, 2014,124(7-8): 380-386.
[9]
Zhao S, Li R, Cai X, et al. The application of SILAC mouse in human body fluid proteomics analysis reveals protein patterns associated with IgA nephropathy [J]. Evid Based Complement Alternat Med, 2013,2013: 275390.
[10]
Kalantari S, Rutishauser D, Samavat S, et al. Urinary prognostic biomarkers and classification of IgA nephropathy by high resolution mass spectrometry coupled with liquid chromatography [J]. PLoS One, 2013,8(12): e80830.
[11]
Rocchetti MT, Papale M, d′Apollo AM, et al. Association of urinary laminin G-like 3 and free K light chains with disease activity and histological injury in IgA nephropathy [J]. Clin J Am Soc Nephrol, 2013,8(7): 1115-1125.
[12]
Surin B, Sachon E, Rougier JP, et al. LG3 fragment of endorepellin is a possible biomarker of severity in IgA nephropathy [J]. Proteomics, 2013,13(1): 142-152.
[13]
Sogabe A, Uto H, Kanmura S, et al. Correlation of serum levels of complement C4a desArg with pathologically estimated severity of glomerular lesions and mesangial hypercellularity scores in patients with IgA nephropathy [J]. Int J Mol Med, 2013,32(2): 307-314.
[14]
Lewandowicz A, Bakun M, Kohutnicki R, et al. Changes in urine proteome accompanying diabetic nephropathy progression [J]. Pol Arch Med Wewn, 2015,125(1-2): 27-38.
[15]
Zubiri I, Posada-Ayala M, Benito-Martin A, et al. Kidney tissue proteomics reveals regucalcin downregulation in response to diabetic nephropathy with reflection in urinary exosomes [J]. Transl Res, 2015,166(5): 474-484.
[16]
Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy [J]. N Engl J Med, 2009, 361(1): 11-21.
[17]
Rood IM, Merchant ML, Wilkey DW, et al. Increased expression of lysosome membrane protein 2 in glomeruli of patients with idiopathic membranous nephropathy [J]. Proteomics, 2015, 15(21): 3722-3730.
[18]
Cruz DN, de Cal M, Garzotto F, et al. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population [J]. Intensive Care Med, 2010, 36(3): 444-451.
[19]
Aregger F, Uehlinger DE, Witowski J, et al. Identification of IGFBP-7 by urinary proteomics as a novel prognostic marker in early acute kidney injury [J]. Kidney Int, 2014, 85(4): 909-919.
[20]
Bonventre JV, Vaidya VS, Schmouder R, et al. Next-generation biomarkers for detecting kidney toxicity [J]. Nat Biotechnol, 2010, 28(5): 436-440.
[21]
Bosso N, Chinello C, Picozzi SC, et al. Human urine biomarkers of renal cell carcinoma evaluated by ClinProt [J]. Proteomics Clin Appl, 2008, 2(7-8): 1036-1046.
[22]
Sandim V, Pereira Dde A, Kalume DE, et al. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma [J]. Urol Oncol, 2016, 34(1): 11-25.
[23]
DI Carlo A. Matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 and -2 in sera and urine of patients with renal carcinoma [J]. Oncol Lett, 2014, 7(3): 621-626.
[24]
Shalabi A, Abassi Z, Awad H, et al. Urinary NGAL and KIM-1: potential association with histopathologic features in patients with renal cell carcinoma [J]. World J Urol, 2013, 31(6): 1541-1545.
[25]
Raimondo F, Morosi L, Corbetta S, et al. Differential protein profiling of renal cell carcinoma urinary exosomes [J]. Mol Biosyst, 2013, 9(6): 1220-1233.
[26]
Lu Y, Liu X, Shi S, et al. Bioinformatics analysis of proteomic profiles during the process of anti-thy1 nephritis [J]. Mol Cell Proteomics, 2012, 11(4): M111 008755.
[27]
Lu Y, Cai G, Cui S, et al. FHL2-driven molecular network mediated Septin2 knockdown inducing apoptosis in mesangial cell [J]. Proteomics, 2014, 14(21-22): 2485-2497.
[28]
Lu Y, Chen X, Yin Z, et al. Screening for potential serum biomarkers in rat mesangial proliferative nephritis [J]. Proteomics, 2016, 16(6): 1015-1022.
[1] 费一鸣, 刘卓, 张丽娟. 组学分析在早产分子机制中的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 504-510.
[2] 周涵, 武胡雯, 张培深, 邓晗彬, 范闻轩, 李嘉诚, 程少文. 蛋白质组学在慢性难愈合创面研究中的应用进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 536-540.
[3] 黄兴, 王蕾, 夏丹. 靶向免疫治疗时代下减瘤性肾切除术在转移性肾细胞癌治疗中的价值[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 208-213.
[4] 周慧宇, 吕定阳, 双卫兵. 联合系统性免疫炎症指数和预后营养指数预测腹腔镜肾切除术后肾癌患者的预后[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 225-231.
[5] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[6] 中华医学会器官移植学分会, 中国医师协会器官移植医师分会. 中国肝移植受者肾损伤管理临床实践指南(2023版)[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 276-288.
[7] 程柏凯, 杨光. 高胰岛素-正葡萄糖钳夹技术评估慢性肾脏病患者胰岛素抵抗的研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 334-339.
[8] 郭俊楠, 林惠, 任艺林, 乔晞. 氨基酸代谢异常在急性肾损伤向慢性肾脏病转变中的作用研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 283-287.
[9] 冯熔熔, 苏晓乐, 王利华. 慢性肾脏病患者并发心血管疾病相关生物标志物研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 273-278.
[10] 涂晓文. 糖尿病肾脏病的靶点药物研发进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(04): 240-240.
[11] 刘俊, 陈客宏. 终末期肾脏病患者运动干预的作用研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(04): 219-225.
[12] 陆文琪, 赵艳茹, 李焕娣, 樊欣娜, 王佳, 李萍. 2型糖尿病患者血清SMAD2和SOX6表达及其与蛋白尿的关系[J/OL]. 中华肾病研究电子杂志, 2024, 13(03): 145-151.
[13] 王小龙, 吴杰, 段姝伟, 王超卉, 潘娜, 白圆圆, 李航天, 蔡广研. 不同等级体力活动对慢性肾脏病患者预后的影响[J/OL]. 中华肾病研究电子杂志, 2024, 13(03): 121-128.
[14] 何娅妮. 糖尿病肾脏病患者的血糖监测评估与降糖治疗[J/OL]. 中华肾病研究电子杂志, 2024, 13(03): 180-180.
[15] 奚培培, 周加军. 慢性肾脏病患者肌少症机制和诊治的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 491-495.
阅读次数
全文


摘要